CVID: Diagnosis, EUROclass Phenotyping, IVIG/SCIG, Genetic Testing
Executive Summary
1. Immunopathogenesis & B-Cell Defect
CVID is fundamentally a defect in B-cell maturation, class switching, and antibody production. The diagnostic hallmark is hypogammaglobulinemia with poor vaccine response — patients fail to mount durable IgG responses to neoantigens (polysaccharide vaccines like pneumococcal PPSV23, protein vaccines like tetanus). Most patients have intact T-cell numbers but variable T-cell function defects, particularly in T-follicular helper cells supporting B-cell maturation in germinal centers.
The unifying immunophenotype is profoundly reduced switched memory B cells (CD27+IgD-IgM-, often <2% of total B cells) — this is the substrate for the EUROclass classification system. About 20-30% of patients also show abnormal transitional B-cell populations (CD27-IgD+IgM++), which correlate with autoimmune and lymphoproliferative complications.
Genetically, ~25% of CVID is now attributable to monogenic causes, expanding rapidly with NGS panels. Key examples: NFKB1 haploinsufficiency (~5-10% of CVID, autoimmunity-prominent), CTLA4 haploinsufficiency (autoimmunity, GI disease, lymphoproliferation — treatable with abatacept), PIK3CD GOF (activated PI3K-delta syndrome, lymphadenopathy, EBV susceptibility — treated with selective PI3Kδ inhibitors or sirolimus). The remaining 75% is polygenic or environmentally modulated. Genetic testing is now standard at diagnosis and can directly change therapy.
2. Diagnosis — ESID/PAGID Criteria + EUROclass
The 2014 revised ESID criteria define CVID as:
- Marked reduction of IgG (≥2 SD below mean for age) AND
- Marked reduction of at least one of IgA or IgM AND
- Poor vaccine response (failure to mount protective response to polysaccharide and/or protein antigens) OR low switched memory B cells (<70% of age-matched controls) AND
- Onset of symptoms ≥4 years of age AND
- Exclusion of secondary hypogammaglobulinemia (medications, B-cell malignancy, protein loss, infection)
Common secondary causes to rule out: rituximab/anti-CD20, prolonged steroids, antiepileptics, anti-malarials; chronic lymphocytic leukemia, multiple myeloma, lymphoma; nephrotic syndrome, protein-losing enteropathy; HIV, EBV. A thorough medication and disease review is mandatory before labeling CVID — secondary hypogammaglobulinemia is more common than primary.
EUROclass phenotyping (immunological severity stratification):
| Class | Switched memory B | Transitional B | Clinical association |
|---|---|---|---|
| smB+ | ≥2% | Normal | Predominantly infection-only phenotype |
| smB- | <2% | Normal | Higher autoimmunity + GLILD risk |
| smB- Trnorm | <2% | Normal | Granulomatous disease prominent |
| smB- Trhi | <2% | ↑ (>9%) | Lymphoid hyperplasia, splenomegaly |
Genetic testing: NGS panel (50-100 immunodeficiency genes) is now first-line at diagnosis or after first major complication. About 25% of patients have an identified monogenic cause — many of which change management.
3. IVIG / SCIG Replacement Therapy
Lifelong immunoglobulin replacement is the cornerstone of CVID management. Two routes are equivalent in efficacy and chosen based on patient preference, vascular access, lifestyle, and adverse event profile:
IVIG (intravenous immunoglobulin)
- Dose: 400-600 mg/kg q3-4 weeks (typically rounded to nearest vial size)
- Target: trough IgG ≥600 mg/dL; bronchiectasis or GLILD patients often need higher (≥800 mg/dL)
- Setting: outpatient infusion center; first dose monitored for reactions
- Pros: single infusion every 3-4 weeks, supervised setting
- Cons: peak/trough variation (peak high then drift down — ‘wear-off’ phenomenon at end of cycle), infusion reactions (~5%), thromboembolic risk (rare but important)
SCIG (subcutaneous immunoglobulin)
- Dose: ~100-200 mg/kg/week divided into 1-2 infusions; or facilitated SCIG (recombinant hyaluronidase + Ig 10-20%) every 3-4 weeks
- Target: same trough goal, with steady-state pharmacokinetics
- Setting: home infusion after training
- Pros: patient-administered, steady-state IgG (no peak/trough swings), fewer systemic reactions, no IV access needed
- Cons: local site reactions, weekly time commitment
Pre-medication
Acetaminophen 650 mg + diphenhydramine 25 mg before each IVIG infusion in patients with prior reactions; hydrate well; slow infusion rates (max 0.08 mL/kg/min) for first hour. Avoid in IgA-deficient patients with anti-IgA antibodies (use IgA-depleted product). Aspirin or low-dose anticoagulation in high thromboembolic risk patients.
4. Complication Management & Surveillance
Beyond infections, CVID has a high burden of non-infectious complications that drive late mortality. Surveillance must be lifelong and structured:
Pulmonary — bronchiectasis & GLILD
- HRCT chest at baseline + every 2-3 years (or sooner for symptoms). Bronchiectasis is found in 30-50% even with adequate IgG replacement. Higher trough IgG (≥800-1000 mg/dL) slows progression.
- GLILD (granulomatous-lymphocytic ILD): 10-20% prevalence, drives mortality. PFTs every 6-12 months; HRCT at suspicion. Treatment: rituximab + azathioprine (combined regimen has best evidence); steroids alone are inadequate.
Autoimmunity
- Cytopenias (ITP, AIHA, neutropenia) in 10-25%; treat with rituximab as steroid-sparing; mycophenolate; consider sirolimus for refractory.
- Organ-specific autoimmunity: thyroid (5-10%), GI (atrophic gastritis 25%), pernicious anemia.
GI — CVID enteropathy
- Chronic diarrhea, weight loss, malabsorption. Endoscopy with biopsies (lymphoid hyperplasia, sprue-like changes, granulomas, T-cell infiltration). Rule out giardia, norovirus, CMV. Treatment: budesonide, vedolizumab if Crohn-like.
Lymphoproliferation & malignancy
- Splenomegaly common; lymphadenopathy needs biopsy if persistent. Lymphoma risk ~10× population — non-Hodgkin lymphoma, especially MALT and DLBCL.
- Annual physical exam + lymph node survey; imaging (CT/MRI) for unexplained constitutional symptoms.
Vaccinations
- Avoid all live vaccines (MMR, varicella, BCG, oral polio, oral typhoid, yellow fever).
- Inactivated vaccines (influenza, COVID, pneumococcal conjugate) are safe and may provide partial protection. Annual flu vaccine recommended.
5. Genetic Testing & Future Directions
The CVID landscape is being reshaped by accessible genetic testing. About 25% of patients carry an identifiable monogenic cause, and several of these mutations have specifically targetable therapies beyond Ig replacement:
| Gene | Mechanism | Phenotype | Targeted therapy |
|---|---|---|---|
| CTLA4 | Haploinsufficiency | Autoimmunity, GI, lymphoproliferation | Abatacept (CTLA4-Ig) |
| PIK3CD (APDS) | Gain-of-function | Lymphadenopathy, EBV, lymphoma | Leniolisib or sirolimus |
| NFKB1 | Haploinsufficiency | Autoimmunity, infections | Rituximab, mycophenolate; HSCT in severe |
| LRBA | Loss | Autoimmunity, enteropathy, ILD | Abatacept, sirolimus |
| STAT3 GOF | Gain-of-function | Multiorgan autoimmunity | Tocilizumab, JAK inhibitors |
For patients without identified monogenic cause but with severe complications (refractory autoimmunity, GLILD, lymphoma), hematopoietic stem cell transplantation is increasingly considered — outcomes are improving but remain higher risk than chronic Ig replacement. Decision belongs in dedicated immunodeficiency center.
Pearl
Refractory autoimmunity, GLILD, severe lymphoproliferation, or family history of immunodeficiency should prompt NGS panel testing. Even when not changing therapy, genetic confirmation aids family counseling and prognostic accuracy.Pitfall
Treating recurrent infections in a patient who is actually on rituximab or chemotherapy as ‘CVID’ is a common error. Always document immunosuppressive medication exposure first; secondary hypogammaglobulinemia from B-cell depletion is far more common than primary CVID.6. Practice Insights
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)CVID is a decades-long disease. Many patients are diagnosed in their 30s after years of misattributed sinopulmonary infections, treated initially with antibiotics alone, and only later transitioned to lifelong immunoglobulin. The most striking pattern in long-term follow-up is how often complications — not infections themselves — drive second-decade mortality.
What the Guideline Misses
ESID criteria are well-defined for diagnosis, but the timing of genetic testing isn’t standardized in routine practice. The stronger position is an NGS panel at diagnosis — not after the first complication — because identifying CTLA4 or PIK3CD changes therapy fundamentally, and waiting until autoimmunity emerges means scarring has already started. The yield is ~25% but the management impact is disproportionate.
Patterns That Recur
GLILD develops insidiously over years and is the single biggest mortality driver in CVID. Patients tolerate baseline cough or mild dyspnea as ‘CVID-related’ and do not escalate, while HRCT shows progressive nodules and ground glass. Imaging every 18-24 months even in asymptomatic smB- patients is therefore justified — catching GLILD early changes outcomes more than any other surveillance practice. The other pattern: patients on stable IVIG for years still develop bronchiectasis if trough <800, so higher troughs are the sensible default in those with established lung disease.
A Bedside Heuristic
When a CVID patient presents with new constitutional symptoms (weight loss, drenching sweats, fatigue beyond infection), the working assumption should be ‘lymphoma until proven otherwise.’ This is over-vigilance compared to baseline rates, but the 10× excess risk plus the silent presentation of MALT/DLBCL in this population justifies low threshold for imaging + biopsy. False positives outweigh missed lymphoma every time.
Anonymized case
A 38-year-old woman presented with 15 years of recurrent sinusitis and bronchitis attributed to ‘allergies.’ Workup revealed IgG 380 (low), IgA <7 (low), poor pneumococcal vaccine response — meeting CVID criteria. NGS panel revealed heterozygous NFKB1 mutation. She had occult bronchiectasis on baseline HRCT (asymptomatic at the time) and ITP (platelet 75) — both fitting NFKB1 phenotype. Started IVIG 600 mg/kg q4 weeks (trough goal >800 given bronchiectasis), rituximab × 2 doses for ITP, and surveillance HRCT. By year 3, no new infections, stable bronchiectasis, ITP in remission. Genetic counseling identified a 16-year-old daughter as a heterozygous carrier; she’s now in pre-symptomatic immunology follow-up.
→ Early NGS testing identified a treatable monogenic cause (NFKB1) that changed management; baseline HRCT caught asymptomatic bronchiectasis and prompted higher trough targeting; family genetic counseling identified a pre-symptomatic relative for surveillance.
Protocol Adjustments Beyond the Standard Guideline
- clinicians order NGS immunodeficiency panel at the first immunology visit, not deferred — about 1 in 4 yields a monogenic cause that changes management.
- For patients with bronchiectasis or GLILD, target an IgG trough ≥800 (not 600) — bronchiectasis progression slows measurably at this threshold.
- Image (HRCT) every 18-24 months in smB- phenotype patients regardless of symptoms — GLILD is the primary mortality driver and is silent until advanced.